FdaApplication
NDA 218213
Identifiers
- fda_app_no: NDA218213
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2023-11-15 |
Revenue by product
AUGTYRO
| Period | Revenue |
|---|---|
| Q4 2024 | $15.0M |
| Q3 2024 | $10.0M |
| Q2 2024 | $7.0M |
| Q1 2024 | $6.0M |
| Q4 2023 | $1.0M |
| Q3 2023 | $0.0M |
| Q2 2023 | $0.0M |
| Q1 2023 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AUGTYRO | REPOTRECTINIB | 40MG | CAPSULE;ORAL |
| AUGTYRO | REPOTRECTINIB | 160MG | CAPSULE;ORAL |
2 products